Xanomeline/trospium chloride

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

SchizophreniaMania

174 competitors in Schizophrenia

#DrugCompanyPhaseTrials

1

Xanomeline/trospium chloride

Bristol-Myers Squibb

Phase 3

12

Resotran

Takeda

Preclinical

13

Inapsine

Jazz Pharmaceuticals

Preclinical

14

Ozempic

Novo Nordisk

Preclinical

15

Depakote

AbbVie

Preclinical

—6

Ibrance

Pfizer

Preclinical

—7

Lunesta

Akero Therapeutics

Preclinical

38

Luvox

SSolvay Pharmaceuticals

Preclinical

19

Catapres

Boehringer Ingelheim

Preclinical

110

Rapamune

PPrism Pharmaceuticals

Preclinical

1Show 31 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Tics1 trial

A Study to Evaluate the Effects of Lithium, Valproic Acid, and Lamotrigine on the Pharmacokinetics of KarXT and Effects of KarXT on the Pharmacokinetics of Lithium, Valproic Acid, and Lamotrigine in Healthy Participants

Completed·KKaruna Therapeutics·Phase 1·NCT06729970·133 enrolled

Alzheimer disease1 trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

Recruiting·Bristol-Myers Squibb·Phase 3·NCT07011732·426 enrolled

Alzheimer's Disease1 trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)

Recruiting·Bristol-Myers Squibb·Phase 3·NCT07011745·426 enrolled

Schizophrenia1 trial

A Phase 3 Double-blind, Placebo-controlled Randomized Withdrawal Maintenance Trial of KarXT Treatment in Participants With Schizophrenia

Recruiting·KKaruna Therapeutics, Inc., a Bristol Myers Squibb company·Phase 3·NCT07686263·472 enrolled

Mania1 trial

A Phase 3, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Individuals With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

Recruiting·Bristol-Myers Squibb·Phase 3·NCT07140913·424 enrolled

1 more indication

Unspecified3 trials

A Study to Evaluate the Effect of KarXT on Urological Safety

Recruiting·Bristol-Myers Squibb·Phase 4·NCT07221877·60 enrolled

Phase 1, 4-Part, Open-label (Parts 1 to 3) and Double-blind (Part 4) Study to Evaluate the Pharmacokinetics of Novel KarX (BMS-986519) and KarT (BMS-986520) Prototypes Versus the KarXT (BMS-986510) and KarX-EC (BMS-986519) Reference Following Single Doses, and to Explore the Effect of Food After Multiple Doses of Selected Prototypes in Healthy Adult Participants, and to Evaluate Alternative Formulations of KarX (BMS-986519) and KarXT (BMS-986510) Following Single and Multiple Ascending Doses in Healthy Adult Participants

Recruiting·Bristol-Myers Squibb·Phase 1·NCT07063342·236 enrolled

A Phase IV, Open-label, Single-group Study Evaluating KarXT Concentrations in the Breast Milk and Plasma of Healthy Lactating Female Participants

Completed·KKaruna Therapeutics·Approved·NCT07257120·10 enrolled

Details

Drug Info

Related News